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Genetic Profiling in Acute Myeloid Leukemia
To the Editor: In their article on the prognostic 
relevance of integrated genetic profiling in pa-
tients with acute myeloid leukemia (AML), Patel 
et al. (March 22 issue)1 propose an elaborate risk-
stratification system for refining prognosis for 
patients with intermediate-risk AML. This strati-
fication is based on mutational analysis by DNA 
sequencing of 10 individual leukemia genes in 
addition to standard karyotyping. However, even 
ignoring the impracticality of such an analysis, 
we consider this risk stratification to be overly 
complicated and unjustified. Instead, on the ba-
sis of the report’s supplementary data, we believe 
that only two genes are worthy of mutational 
screening, DNMT3A and MLL. Mutations in either 
of these genes predict adverse outcomes indepen-
dent of other mutations, including internal tan-
dem duplication in FLT3 (FLT3-ITD), as reported 
previously.2 Moreover, DNMT3A and MLL muta-
tions define a biologic subgroup of AML patients 
typically presenting with myelomonocytic or 
blastic morphology and marked leukocytosis3 
who may benefit from escalation of induction 
chemotherapy with dose-intensified daunorubi-
cin.4 We propose that rapid identification of un-
favorable mutations in DNMT3A and partial tan-
dem duplication in MLL (MLL-PTD) alone is 
required for guiding optimal treatment in pa-
tients with newly diagnosed AML.
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The authors reply: As the correspondents sug-
gest, the addition of diagnostic testing for muta-
tions in DNMT3A and MLL-PTD to karyotypic 
evaluation would improve prognostication in pa-
tients with AML. However, restricting molecular 
studies to these two genes would not capture all 
patients with molecularly defined unfavorable-
risk disease. Specifically, 41% of patients with risk 
that is unfavorable on the basis of our integrated 
genetic classification would remain in the inter-
mediate-risk cohort without additional mutational 
data. We recognize that full-length resequencing 
of a set of informative genes in the clinical set-
ting is a labor-intensive effort. However, with the 
plummeting cost of sequencing, focused next-
generation sequencing is now a potentially viable 
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option for mutational studies. The goal of our 
study was to identify all genes known to be mu-
tated in AML with potential clinical relevance 
when integrated with current cytogenetic evalua-
tion and to validate their prognostic relevance. 
Given the increasing affordability of sequencing 
technology, we believe that the cost of identify-
ing each additional patient who would benefit 
from more detailed mutational profiling, as 
compared with the more limited diagnostic eval-
uation suggested by the correspondents, is com-
pletely justifiable.
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Device Closure for Stroke with Patent Foramen Ovale
To the Editor: Furlan et al. (March 15 issue)1 
report no benefit from the closure of a patent 
foramen ovale in patients with cryptogenic 
stroke. Several issues deserve comment.
First, it is unclear how many study patients 
truly had cryptogenic stroke (30% had hyperten-
sion and 20% smoked, which suggests that 
some may have had lacunar strokes). It is of in-
terest that most of the recurrent strokes (81%) 
were not considered to be clearly cryptogenic 
(including some that may have been explained 
by lacunar infarction in patients with risk fac-
tors). Second, among patients with shunts of 
moderate or substantial size, the estimated re-
duction in risk of stroke is 35%. The decision to 
include patients at low risk may have diluted the 
actual protective effect of the device in patients 
at higher risk.
Furthermore, the protocol specified the use 
of antiplatelet agents in the closure group, al-
though 97 of the patients in this group had 
previously been taking warfarin. Was warfarin 
withdrawn in the closure group while being al-
lowed in some patients in the medical-therapy 
group? Patent foramen ovale closure is associat-
ed with a risk of atrial fibrillation that is eight 
times as high as that among patients assigned 
to medical therapy. This issue may be critical, 
since double antiplatelet therapy has been shown 
to be inferior to warfarin in patients with atrial 
fibrillation.2
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To the Editor: Several factors could limit the 
translation of CLOSURE I (Evaluation of the 
STARFlex Septal Closure System in Patients with 
a Stroke and/or Transient Ischemic Attack due to 
Presumed Paradoxical Embolism through a Pat-
ent Foramen Ovale) into clinical practice. Some 
patients with large redundant atrial septal aneu-
rysms were excluded, although such aneurysms 
are an important risk factor for recurrent embo-
lism.1 The STARFlex device (NMT Medical) is no 
longer available; the rates of residual shunt and 
thrombus associated with this device were high-
er than those associated with other devices.2 Pa-
tients at highest risk for recurrence may have 
been treated outside the trial or may have re-
ceived other devices. In addition, the complica-
tion rate is much higher and the success rate 
lower in CLOSURE I than has been previously 
reported.3 Finally, it is an underpowered trial; 
thus, the possibility of clinical benefit from clo-
sure cannot be ruled out.
In our opinion, this trial demonstrates the 
importance of patient selection (i.e., excluding 
patients with alternative causes of stroke) and 
the need to concentrate the use of these inter-
ventions at high-volume centers with low rates 
of procedural complications and high success 
rates. Such centers can complete the ongoing 
randomized trials that will contribute informa-
tion additional to that provided by CLOSURE I 
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